EGFR and alveolar rhabdomyosarcoma: Another reason for the lack of activity of Erlotinib may have been that Egfr might heterodimerize with Her2, raising the possibility that targeting the Egfr:Her2 heterodimers might be a better therapeutic strategy in alveolar rhabdomyosarcoma.